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Introduction
Stevens-Johnson syndrome (SJS) is a relatively rare
but severe disease characterized by exfoliative
dermatitis, and accompanied by fever, inflammation
of the gastrointestinal mucosa, and severe purulent
conjunctivitis. It is often associated with high morbid-
ity and mortality, depending on patient age and the
underlying condition. The causes of SJS may be
iatrogenic, infectious or idiopathic. The most com-
mon causes of drug-induced SJS are antibiotics
(cephalosporins, erythromycin, penicillins, sul-
fonamides, and tetracycline) and anticonvulsants
(carbamazepine, phenobarbital, and phenytoin).1–3
Chlordiazepoxide (Librium®; Roche Laboratories,
Nutley, NJ, USA), a benzodiazepine sedative used
extensively in the treatment of anxiety states, insomnia,
and alcohol withdrawal, has not previously been
associated with SJS. Here, we describe a case of SJS
induced by chlordiazepoxide overdose.
Case Report
A 38-year-old, single, Asian male, previously in good
health, was admitted with the chief complaints of sore
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throat, malaise and fever. He had taken 1,000
chlordiazepoxide 10 mg tablets in a suicide attempt,
after a conflict with his girlfriend. He had slept at home
for 2 days, and then awoke with a severe sore throat.
He visited our outpatient department for help, and
was admitted because of his poor general condition.
The patient denied taking any other drugs before,
or during, this event. No previous history of asthma,
or skin or drug allergy, was claimed. The patient
looked very ill, but had clear consciousness. Vital signs
were as follows: temperature, 40$C; pulse rate, 104
beats/minute; respiratory rate, 22 breaths/minute;
blood pressure, 144/90 mmHg. Physical examination
revealed severe oral ulceration, and a diffuse macular
rash and multiple bullous lesions on the trunk and
extremities, but no genital ulceration was found. An
eye examination revealed teariness, congestion, and
subconjunctival hemorrhage.
Laboratory tests showed a white blood cell count
of 12.3 = 109/L, hemoglobin of 15.6 g/dL, and
platelet count of 288,000/mm.3 The differential counts
of segmented neutrophils, lymphocytes, monocytes,
and eosinophils were 71.4%, 18.3%, 8.5%, and 1.0%,
respectively. Electrolytes, liver enzymes, and renal
function tests were within normal limits. The level of
C-reactive protein (CRP) was 15.5 mg/dL (normal,
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< 0.5 mg/dL). Drug screen tests of urine and serum
for opiates, phencyclidine, cocaine, paraquat, bar-
biturates, phenytoin, acetaminophen, cannabinoids,
and methaqualone, were negative. Total immu-
noglobulin (Ig) E and total eosinophil counts were
2,263 kU/L (normal, < 300 kU/L) and 200/mm3
(normal, < 200/mm3), respectively. Antinuclear
antibody was not detected. Chest X-ray was normal,
without signs of infiltration. Tests for herpes simplex
virus IgM, and an enzyme-linked immunosorbent
assay for anti-HIV antibodies, were negative.
Mycoplasma pneumoniae particle agglutination and
cold agglutinin tests were also negative.
The time of symptoms relative to the ingestion of
chlordiazepoxide led to a diagnosis of chlordia-
zepoxide-induced SJS. Subsequently, empirical
antibiotic therapy with pefloxacin and clindamycin
was prescribed for high fever and severe oral ulceration.
However, bacterial cultures of blood, sputum and
urine samples were negative during hospitalization.
Fever subsided after antibiotic therapy. On the third
day after admission, methylprednisolone (40 mg every
8 hours) was prescribed. Although oral ulceration
reduced slowly, the patient’s generalized skin lesions
improved gradually within 3 weeks, without scar
formation. Therefore, 3 weeks after admission, the
methylprednisolone dosage was tapered gradually.
Total IgE and CRP levels measured 3 weeks later
were 455 kU/L and 0.34 mg/dL, respectively. The
patient was discharged in a stable condition and
advised against the future use of benzodiazepine-
related sedatives.
Discussion
SJS, first described in 1922,4 is a rare but life-
threatening disease. It presents as a bullous form of
erythema multiforme, with extensive mucocutaneous
reactions. The incidence of SJS is estimated at 1–6
cases per million person-years and, although rare,
may contribute to severe complications and death.5
The mortality rate associated with SJS varies widely
from 5% to 30%, depending on patient age and the
underlying condition.6
Drug-induced SJS has been associated with vari-
ous medications, the most notorious of which are
antibiotics (cephalosporins, erythromycin, penicillins,
sulfonamides, and tetracycline) and anticonvulsants
(carbamazepine, phenobarbital, and phenytoin).1–3
Other drugs suspected of contributing to SJS include
chlorpropamide,2 allopurinol, nonsteroidal anti-
inflammatory agents,7 aspirin, and phenolphthalein-
containing laxatives.8 However, the mechanisms, which
may involve hypersensitivity reactions to drugs and
their metabolites, are not yet known.2 The most
popular concept, although not universally accepted, is
that SJS is an immunologic disease. Non-drug causes
of SJS include infections (M. pneumoniae, herpes
simplex virus) and idiopathic factors.2
Benzodiazepines are used extensively in the
treatment of anxiety, insomnia, and alcohol withdrawal
syndrome. Although bullae have been reported after
overdosage with oxazepam,9 a MEDLINE search using
the key terms “Stevens-Johnson syndrome” and
“benzodiazepines” revealed no direct evidence of
benzodiazepine-induced SJS. SJS usually presents with
prodromal symptoms of fever, sore throat, malaise,
dysphagia, and conjunctivitis. Some of the most
characteristic findings in SJS that differentiate the
condition from erythema multiforme are severe
inflammation and erosion of the mucosal membranes
of the oropharyngeal cavity, as well as genitourinary
involvement. Considering the time of symptoms and
the drug history, we concluded that our patient had
chlordiazepoxide-induced SJS. However, a dose-
related response has not been clearly identified in
previous reports and now warrants further study.
The effective management of drug-induced SJS
requires prompt recognition of the condition,
withdrawal of the causative drugs as soon as possible,
and initiation of appropriate supportive therapy.
If there is a strong suspicion of SJS or toxic epidermal
necrolysis, prompt withdrawal of drug treatment will
reduce the risk of death by about 30% per day.10 It
remains controversial as to whether corticosteroids are
beneficial in treating patients with SJS. Several case
reports and short studies advocate the use of high-
dose corticosteroids, based on the rationale that muco-
cutaneous lesions are a hypersensitivity response,11–13
and systemic corticosteroids may cause faster reso-
lution of fever, malaise and skin lesions than would
otherwise be the case. Conversely, several reports
suggest that corticosteroid use in patients with SJS
increases morbidity and mortality from infectious
complications.14 Thus, well-controlled, prospective,
double-blind studies are needed to verify the effects of
corticosteroids in patients with SJS.
In conclusion, we present the case of a patient with
chlordiazepoxide-induced SJS who was treated
successful ly with supportive measures and
corticosteroid therapy. We did not rechallenge the
patient with benzodiazepines because of the high risk
of SJS complications. In summary, extremely high
doses of benzodiazepines can cause severe drug
reactions such as, in this case, SJS.
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